CollPlant Biotechnologies (CLGN) Competitors

$0.32 -0.01 (-4.10%)

As of 04:00 PM Eastern

CLGN vs. OSRH, APLT, HIND, PASG, and KALA

Should you buy CollPlant Biotechnologies stock or one of its competitors? CollPlant Biotechnologies's main competitors and comparable companies include OSR (OSRH), Applied Therapeutics (APLT), Vyome (HIND), Passage Bio (PASG), and KALA BIO (KALA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does CollPlant Biotechnologies compare to OSR?

CollPlant Biotechnologies (NASDAQ:CLGN) and OSR (NASDAQ:OSRH) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, earnings and risk.

In the previous week, OSR had 2 more articles in the media than CollPlant Biotechnologies. MarketBeat recorded 2 mentions for OSR and 0 mentions for CollPlant Biotechnologies. CollPlant Biotechnologies' average media sentiment score of 0.00 equaled OSR'saverage media sentiment score.

Company	Overall Sentiment
CollPlant Biotechnologies	Neutral
OSR	Neutral

CollPlant Biotechnologies has a beta of 1.67, suggesting that its share price is 67% more volatile than the broader market. Comparatively, OSR has a beta of 0.55, suggesting that its share price is 45% less volatile than the broader market.

CollPlant Biotechnologies has higher earnings, but lower revenue than OSR. OSR is trading at a lower price-to-earnings ratio than CollPlant Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CollPlant Biotechnologies	$2.37M	1.98	-$11.49M	-$1.45	N/A
OSR	$2.91M	4.96	-$27.06M	-$0.33	N/A

OSR has a net margin of -363.26% compared to CollPlant Biotechnologies' net margin of -683.68%. OSR's return on equity of -7.24% beat CollPlant Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CollPlant Biotechnologies	-683.68%	-218.81%	-139.28%
OSR	-363.26%	-7.24%	-5.41%

21.7% of CollPlant Biotechnologies shares are owned by institutional investors. Comparatively, 55.3% of OSR shares are owned by institutional investors. 9.6% of CollPlant Biotechnologies shares are owned by company insiders. Comparatively, 36.9% of OSR shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

CollPlant Biotechnologies presently has a consensus target price of $11.50, suggesting a potential upside of 3,439.55%. Given CollPlant Biotechnologies' stronger consensus rating and higher probable upside, equities analysts plainly believe CollPlant Biotechnologies is more favorable than OSR.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CollPlant Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
OSR	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

OSR beats CollPlant Biotechnologies on 9 of the 14 factors compared between the two stocks.

How does CollPlant Biotechnologies compare to Applied Therapeutics?

CollPlant Biotechnologies (NASDAQ:CLGN) and Applied Therapeutics (NASDAQ:APLT) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, media sentiment, dividends and profitability.

CollPlant Biotechnologies has higher revenue and earnings than Applied Therapeutics. Applied Therapeutics is trading at a lower price-to-earnings ratio than CollPlant Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CollPlant Biotechnologies	$2.37M	1.98	-$11.49M	-$1.45	N/A
Applied Therapeutics	$1M	15.86	-$105.62M	-$0.10	N/A

In the previous week, CollPlant Biotechnologies' average media sentiment score of 0.00 equaled Applied Therapeutics'average media sentiment score.

Company	Overall Sentiment
CollPlant Biotechnologies	Neutral
Applied Therapeutics	Neutral

21.7% of CollPlant Biotechnologies shares are owned by institutional investors. Comparatively, 98.3% of Applied Therapeutics shares are owned by institutional investors. 9.6% of CollPlant Biotechnologies shares are owned by company insiders. Comparatively, 1.6% of Applied Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Applied Therapeutics has a net margin of 0.00% compared to CollPlant Biotechnologies' net margin of -683.68%. CollPlant Biotechnologies' return on equity of -218.81% beat Applied Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CollPlant Biotechnologies	-683.68%	-218.81%	-139.28%
Applied Therapeutics	N/A	-340.84%	-175.00%

CollPlant Biotechnologies currently has a consensus target price of $11.50, suggesting a potential upside of 3,439.55%. Applied Therapeutics has a consensus target price of $1.00, suggesting a potential upside of 870.87%. Given CollPlant Biotechnologies' stronger consensus rating and higher probable upside, equities research analysts plainly believe CollPlant Biotechnologies is more favorable than Applied Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CollPlant Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Applied Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

CollPlant Biotechnologies has a beta of 1.67, suggesting that its stock price is 67% more volatile than the broader market. Comparatively, Applied Therapeutics has a beta of 2.08, suggesting that its stock price is 108% more volatile than the broader market.

Summary

CollPlant Biotechnologies beats Applied Therapeutics on 9 of the 14 factors compared between the two stocks.

How does CollPlant Biotechnologies compare to Vyome?

Vyome (NASDAQ:HIND) and CollPlant Biotechnologies (NASDAQ:CLGN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment and earnings.

In the previous week, Vyome's average media sentiment score of 0.00 equaled CollPlant Biotechnologies'average media sentiment score.

Company	Overall Sentiment
Vyome	Neutral
CollPlant Biotechnologies	Neutral

Vyome presently has a consensus target price of $15.00, suggesting a potential upside of 578.73%. CollPlant Biotechnologies has a consensus target price of $11.50, suggesting a potential upside of 3,439.55%. Given CollPlant Biotechnologies' higher possible upside, analysts plainly believe CollPlant Biotechnologies is more favorable than Vyome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vyome	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
CollPlant Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Vyome has higher earnings, but lower revenue than CollPlant Biotechnologies. CollPlant Biotechnologies is trading at a lower price-to-earnings ratio than Vyome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vyome	$320K	48.48	-$10.26M	-$12.27	N/A
CollPlant Biotechnologies	$2.37M	1.98	-$11.49M	-$1.45	N/A

22.1% of Vyome shares are held by institutional investors. Comparatively, 21.7% of CollPlant Biotechnologies shares are held by institutional investors. 33.0% of Vyome shares are held by insiders. Comparatively, 9.6% of CollPlant Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Vyome has a net margin of 0.00% compared to CollPlant Biotechnologies' net margin of -683.68%. Vyome's return on equity of -203.92% beat CollPlant Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vyome	N/A	-203.92%	-134.16%
CollPlant Biotechnologies	-683.68%	-218.81%	-139.28%

Vyome has a beta of 1.48, suggesting that its stock price is 48% more volatile than the broader market. Comparatively, CollPlant Biotechnologies has a beta of 1.67, suggesting that its stock price is 67% more volatile than the broader market.

Summary

Vyome beats CollPlant Biotechnologies on 9 of the 13 factors compared between the two stocks.

How does CollPlant Biotechnologies compare to Passage Bio?

CollPlant Biotechnologies (NASDAQ:CLGN) and Passage Bio (NASDAQ:PASG) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, media sentiment, valuation, dividends, earnings and profitability.

Passage Bio has a net margin of 0.00% compared to CollPlant Biotechnologies' net margin of -683.68%. Passage Bio's return on equity of -150.88% beat CollPlant Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CollPlant Biotechnologies	-683.68%	-218.81%	-139.28%
Passage Bio	N/A	-150.88%	-59.78%

CollPlant Biotechnologies presently has a consensus price target of $11.50, suggesting a potential upside of 3,439.55%. Passage Bio has a consensus price target of $13.25, suggesting a potential upside of 206.71%. Given CollPlant Biotechnologies' higher possible upside, analysts clearly believe CollPlant Biotechnologies is more favorable than Passage Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CollPlant Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Passage Bio	1 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.11

In the previous week, Passage Bio had 2 more articles in the media than CollPlant Biotechnologies. MarketBeat recorded 2 mentions for Passage Bio and 0 mentions for CollPlant Biotechnologies. CollPlant Biotechnologies' average media sentiment score of 0.00 equaled Passage Bio'saverage media sentiment score.

Company	Overall Sentiment
CollPlant Biotechnologies	Neutral
Passage Bio	Neutral

CollPlant Biotechnologies has higher revenue and earnings than Passage Bio. Passage Bio is trading at a lower price-to-earnings ratio than CollPlant Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CollPlant Biotechnologies	$2.37M	1.98	-$11.49M	-$1.45	N/A
Passage Bio	N/A	N/A	-$45.52M	-$11.84	N/A

CollPlant Biotechnologies has a beta of 1.67, meaning that its stock price is 67% more volatile than the broader market. Comparatively, Passage Bio has a beta of 1.44, meaning that its stock price is 44% more volatile than the broader market.

21.7% of CollPlant Biotechnologies shares are held by institutional investors. Comparatively, 53.5% of Passage Bio shares are held by institutional investors. 9.6% of CollPlant Biotechnologies shares are held by insiders. Comparatively, 4.9% of Passage Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

CollPlant Biotechnologies and Passage Bio tied by winning 7 of the 14 factors compared between the two stocks.

How does CollPlant Biotechnologies compare to KALA BIO?

KALA BIO (NASDAQ:KALA) and CollPlant Biotechnologies (NASDAQ:CLGN) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, media sentiment, institutional ownership and risk.

24.6% of KALA BIO shares are owned by institutional investors. Comparatively, 21.7% of CollPlant Biotechnologies shares are owned by institutional investors. 2.2% of KALA BIO shares are owned by company insiders. Comparatively, 9.6% of CollPlant Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

KALA BIO has a beta of -2.26, suggesting that its share price is 326% less volatile than the broader market. Comparatively, CollPlant Biotechnologies has a beta of 1.67, suggesting that its share price is 67% more volatile than the broader market.

In the previous week, KALA BIO had 1 more articles in the media than CollPlant Biotechnologies. MarketBeat recorded 1 mentions for KALA BIO and 0 mentions for CollPlant Biotechnologies. KALA BIO's average media sentiment score of 0.00 equaled CollPlant Biotechnologies'average media sentiment score.

Company	Overall Sentiment
KALA BIO	Neutral
CollPlant Biotechnologies	Neutral

KALA BIO presently has a consensus price target of $1,158.33, indicating a potential upside of 153,321.63%. CollPlant Biotechnologies has a consensus price target of $11.50, indicating a potential upside of 3,439.55%. Given KALA BIO's higher possible upside, equities analysts plainly believe KALA BIO is more favorable than CollPlant Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KALA BIO	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
CollPlant Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

CollPlant Biotechnologies has higher revenue and earnings than KALA BIO. CollPlant Biotechnologies is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KALA BIO	N/A	N/A	-$26.98M	-$96.14	N/A
CollPlant Biotechnologies	$2.37M	1.98	-$11.49M	-$1.45	N/A

KALA BIO has a net margin of 0.00% compared to CollPlant Biotechnologies' net margin of -683.68%. CollPlant Biotechnologies' return on equity of -218.81% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KALA BIO	N/A	-1,336.10%	-94.85%
CollPlant Biotechnologies	-683.68%	-218.81%	-139.28%

Summary

KALA BIO and CollPlant Biotechnologies tied by winning 6 of the 12 factors compared between the two stocks.

Get CollPlant Biotechnologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CLGN vs. The Competition

Export

Metric	CollPlant Biotechnologies	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.89M	$3.70B	$7.02B	$12.98B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-0.22	5.30	210.34	20.96
Price / Sales	1.98	1,255.26	588.78	86.31
Price / Cash	N/A	44.95	28.89	37.42
Price / Book	0.68	17.66	11.27	6.42
Net Income	-$11.49M	-$13.25M	$3.45B	$347.03M
7 Day Performance	2.17%	5.36%	3.56%	2.48%
1 Month Performance	-11.71%	-1.74%	-0.58%	-1.04%
1 Year Performance	-88.60%	61.36%	77.52%	23.22%

CollPlant Biotechnologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CLGN CollPlant Biotechnologies	2.2903 of 5 stars	$0.32 -4.1%	$11.50 +3,439.6%	-88.1%	$4.89M	$2.37M	N/A	70	Gap Up High Trading Volume
OSRH OSR	0.3776 of 5 stars	$0.45 -1.7%	N/A	-26.6%	$15.91M	$2.91M	N/A	N/A	News Coverage Gap Up
APLT Applied Therapeutics	1.521 of 5 stars	$0.10 flat	$1.00 +870.9%	N/A	$15.86M	$1M	N/A	30
HIND Vyome	1.7098 of 5 stars	$2.17 flat	$15.00 +591.2%	N/A	$15.23M	$320K	N/A	50
PASG Passage Bio	3.0427 of 5 stars	$4.69 +1.2%	$13.25 +182.8%	-29.8%	$15.04M	N/A	N/A	130	Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CLGN) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CollPlant Biotechnologies (CLGN) Competitors

CLGN vs. OSRH, APLT, HIND, PASG, and KALA

How does CollPlant Biotechnologies compare to OSR?

Summary

How does CollPlant Biotechnologies compare to Applied Therapeutics?

Summary

How does CollPlant Biotechnologies compare to Vyome?

Summary

How does CollPlant Biotechnologies compare to Passage Bio?

Summary

How does CollPlant Biotechnologies compare to KALA BIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLGN vs. The Competition

CollPlant Biotechnologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CollPlant Biotechnologies (CLGN) Competitors

CLGN vs. OSRH, APLT, HIND, PASG, and KALA

How does CollPlant Biotechnologies compare to OSR?

Does the media refer more to CLGN or OSRH?

Which has more risk & volatility, CLGN or OSRH?

Which has better earnings & valuation, CLGN or OSRH?

Is CLGN or OSRH more profitable?

Do institutionals and insiders have more ownership in CLGN or OSRH?

Do analysts prefer CLGN or OSRH?

Summary

How does CollPlant Biotechnologies compare to Applied Therapeutics?

Which has better valuation & earnings, CLGN or APLT?

Does the media favor CLGN or APLT?

Do insiders and institutionals have more ownership in CLGN or APLT?

Is CLGN or APLT more profitable?

Do analysts prefer CLGN or APLT?

Which has more risk and volatility, CLGN or APLT?

Summary

How does CollPlant Biotechnologies compare to Vyome?

Does the media refer more to HIND or CLGN?

Do analysts rate HIND or CLGN?

Which has stronger earnings and valuation, HIND or CLGN?

Do institutionals and insiders hold more shares of HIND or CLGN?

Is HIND or CLGN more profitable?

Which has more risk and volatility, HIND or CLGN?

Summary

How does CollPlant Biotechnologies compare to Passage Bio?

Is CLGN or PASG more profitable?

Do analysts recommend CLGN or PASG?

Does the media favor CLGN or PASG?

Which has preferable earnings and valuation, CLGN or PASG?

Which has more risk & volatility, CLGN or PASG?

Do institutionals & insiders have more ownership in CLGN or PASG?

Summary

How does CollPlant Biotechnologies compare to KALA BIO?

Do institutionals & insiders believe in KALA or CLGN?

Which has more volatility & risk, KALA or CLGN?

Does the media refer more to KALA or CLGN?

Do analysts rate KALA or CLGN?

Which has preferable valuation and earnings, KALA or CLGN?

Is KALA or CLGN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLGN vs. The Competition

CollPlant Biotechnologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools